Basic Information
| LncRNA/CircRNA Name | DSCAM-AS1 |
| Synonyms | DSCAM-AS1, M41 |
| Region | GRCh38_21:40383083-40385358 |
| Ensemble | ENSG00000235123 |
| Refseq | NR_038896 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | breast cancer |
| ICD-0-3 | C50 |
| Methods | RNA-seq, qPCR, RNAi, RIP, ChIP, Cell proliferation assay etc. |
| Sample | cell lines (T47D, ZR75-1, HEK293, MCF7) |
| Expression Pattern | up-regulated |
| Function Description | Among the luminal breast cancers, DSCAM-AS1 is expressed significantly higher in luminal B, a clinical subtype containing most of the clinically aggressive ER-positive breast cancers. We demonstrate that DSCAM-AS1 mediates tumour progression and tamoxifen resistance and identify hnRNPL as an interacting protein involved in the mechanism of DSCAM-AS1 action. |
| Pubmed ID | 27666543 |
| Year | 2016 |
| Title | The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression. |
External Links
| Links for DSCAM-AS1 | GenBank HGNC NONCODE |
| Links for breast cancer | OMIM COSMIC |